Fast Five Quiz: Castration-Resistant Metastatic and Advanced Prostate Cancer Management

Evelyn S. Marienberg, MD


November 08, 2022

The NCCN recommends that patients being treated for metastatic CRPC should be closely monitored for progression using clinical examination, PSA testing, and radiologic imaging. In addition, ADT should be continued during treatment for CRPC to maintain castration levels of serum testosterone. The NCCN also recommends that patients with a PSADT ≤ 10 months should be treated with a second-generation androgen receptor blocker, but monitoring is the preferred management strategy for those with PSADT > 10 months.

Learn more about the management of metastatic CRPC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.